Christopher Recknor

2.2k total citations
27 papers, 1.6k citations indexed

About

Christopher Recknor is a scholar working on Orthopedics and Sports Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Christopher Recknor has authored 27 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Orthopedics and Sports Medicine, 18 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Christopher Recknor's work include Bone health and osteoporosis research (18 papers), Bone health and treatments (16 papers) and Bone Metabolism and Diseases (12 papers). Christopher Recknor is often cited by papers focused on Bone health and osteoporosis research (18 papers), Bone health and treatments (16 papers) and Bone Metabolism and Diseases (12 papers). Christopher Recknor collaborates with scholars based in United States, Canada and France. Christopher Recknor's co-authors include Bruce Mitlak, Mark Lakshmanan, Harry K. Genant, John H. Krege, Anke Fierlinger, Thomas A. Einhorn, Per Aspenberg, Kyoungah See, Antonio Nino and G. P. Dalsky and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Cancer Research and Clinical Infectious Diseases.

In The Last Decade

Christopher Recknor

26 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Recknor United States	17	1.1k	890	657	328	227	27	1.6k
Ivo Valter United States	17	779 0.7×	685 0.8×	493 0.8×	178 0.5×	100 0.4×	28	1.4k
Joy N. Tsai United States	16	1.4k 1.3×	1.1k 1.2×	934 1.4×	265 0.8×	85 0.4×	27	1.8k
Silvano Adami Italy	13	926 0.9×	667 0.7×	319 0.5×	222 0.7×	89 0.4×	17	1.3k
A Montagnani Italy	24	817 0.8×	501 0.6×	421 0.6×	310 0.9×	174 0.8×	67	1.6k
Y. Boutsen Belgium	16	698 0.6×	485 0.5×	329 0.5×	201 0.6×	158 0.7×	40	1.2k
Christian Muschitz Austria	21	653 0.6×	299 0.3×	437 0.7×	403 1.2×	185 0.8×	72	1.3k
Margaret Paggiosi United Kingdom	19	803 0.7×	373 0.4×	280 0.4×	257 0.8×	153 0.7×	44	1.2k
Stefan Kudlacek Austria	20	411 0.4×	320 0.4×	417 0.6×	165 0.5×	113 0.5×	49	1.0k
Aline G. Costa United States	17	467 0.4×	542 0.6×	459 0.7×	411 1.3×	86 0.4×	24	1.5k
Osvaldo Daniel Messina Argentina	18	530 0.5×	392 0.4×	355 0.5×	156 0.5×	76 0.3×	53	1.3k

Countries citing papers authored by Christopher Recknor

Since Specialization

Citations

This map shows the geographic impact of Christopher Recknor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Recknor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Recknor more than expected).

Fields of papers citing papers by Christopher Recknor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Recknor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Recknor. The network helps show where Christopher Recknor may publish in the future.

Co-authorship network of co-authors of Christopher Recknor

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Recknor. A scholar is included among the top collaborators of Christopher Recknor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Recknor. Christopher Recknor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damm, Timo, Cesar Libanati, Jaime Peña, et al.. (2025). Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density. JBMR Plus. 9(10). ziaf119–ziaf119.

Noureddin, Mazen, Eric Lawitz, Angela Ritter, et al.. (2022). Efficacy and safety of leronlimab in patients with non-alcoholic steatohepatitis: topline results of NASH01 clinical trial. Journal of Hepatology. 77. S713–S713. 1 indexed citations

Cristofanilli, Massimo, Hallgeir Rui, Marek Doležal, et al.. (2022). Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC). Cancer Research. 82(4_Supplement). P5–17. 6 indexed citations

Gaylis, Norman, Angela Ritter, Scott A. Kelly, et al.. (2022). Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome. Clinical Infectious Diseases. 75(7). 1232–1234. 16 indexed citations

Brown, Jacques P., Klaus Engelke, Tony M. Keaveny, et al.. (2021). Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. Journal of Bone and Mineral Research. 36(11). 2139–2152. 44 indexed citations

Recknor, Christopher, et al.. (2019). Functional risk for fracture by safe functional motion testing: a short version of the safe functional motion test. Therapeutic Advances in Musculoskeletal Disease. 11. 1 indexed citations

Adachi, J.D., et al.. (2015). Evolution of subject characteristics in FREEDOM and its extension for up to 8 years. Australasian Journal on Ageing. 34. 64–65. 2 indexed citations

Becker, Clemens, Stephen R. Lord, Stephanie A. Studenski, et al.. (2015). Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. The Lancet Diabetes & Endocrinology. 3(12). 948–957. 279 indexed citations

Zysset, Philippe K., Dieter H. Pahr, Klaus Engelke, et al.. (2015). Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology. Bone. 81. 122–130. 42 indexed citations

10.

Brown, Jacques P., Christian Roux, Pei‐Ran Ho, et al.. (2014). Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporosis International. 25(7). 1953–61. 44 indexed citations

11.

Simon, James A., Christopher Recknor, Alfred H. Moffett, et al.. (2012). Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis. Menopause The Journal of The North American Menopause Society. 20(2). 130–137. 32 indexed citations

12.

Brown, Jacques P., Christian Roux, Ove Törring, et al.. (2012). Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. Journal of Bone and Mineral Research. 28(4). 746–752. 108 indexed citations

13.

Dempster, David W., Hua Zhou, Robert R. Recker, et al.. (2012). Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism. 97(8). 2799–2808. 63 indexed citations

14.

Hadji, Peyman, José Zanchetta, Luis Augusto Tavares Russo, et al.. (2011). The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis International. 23(8). 2141–2150. 98 indexed citations

15.

Cosman, Felicia, Robert A. Wermers, Christopher Recknor, et al.. (2010). Effects of Teriparatide in Postmenopausal Women With Osteoporosis on Prior Alendronate or Raloxifene: Differences Between Stopping and Continuing the Antiresorptive Agent. Obstetrical & Gynecological Survey. 65(3). 179–180. 3 indexed citations

16.

Cosman, Felicia, E.F. Eriksen, Christopher Recknor, et al.. (2010). Effects of once-yearly zoledronic acid 5mg in combination with teriparatide (PTH) on postmenopausal women with osteoporosis. Bone. 47. S55–S56. 2 indexed citations

17.

Cosman, Felicia, Robert A. Wermers, Christopher Recknor, et al.. (2009). Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent. The Journal of Clinical Endocrinology & Metabolism. 94(10). 3772–3780. 125 indexed citations

18.

Emkey, Ronald, Pierre D. Delmas, Michael A. Bolognese, et al.. (2009). Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clinical Therapeutics. 31(4). 751–761. 26 indexed citations

19.

Grbic, John T., Regina Landesberg, Shouqing Lin, et al.. (2008). Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. The Journal of the American Dental Association. 139(1). 32–40. 104 indexed citations

20.

Recker, Robert R., David L. Kendler, Christopher Recknor, et al.. (2006). Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 40(4). 843–851. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact